Bortezomib medac 3 clinical trials

Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy

This study compares a special stem cell treatment to standard care for people with multiple myeloma that has come back or worsened after their first treatment. It aims to see which approach helps people live longer and feel better over five years.